Cargando…

Choosing wisely - when to mend a broken heart with ECMO?

Refractory cardiac shock in the cardiac surgical intensive care unit confers significant morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) has become a common intervention for refractory cardiogenic shock when other therapies have failed. However, it is difficult to predict who wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephens, R Scott, Fan, Eddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059487/
https://www.ncbi.nlm.nih.gov/pubmed/24602370
http://dx.doi.org/10.1186/cc13736
_version_ 1782321250029273088
author Stephens, R Scott
Fan, Eddy
author_facet Stephens, R Scott
Fan, Eddy
author_sort Stephens, R Scott
collection PubMed
description Refractory cardiac shock in the cardiac surgical intensive care unit confers significant morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) has become a common intervention for refractory cardiogenic shock when other therapies have failed. However, it is difficult to predict who will benefit from this costly, resource-intensive, but potentially life-saving technology. Here, we discuss the utility of a novel biomarker, serum butylcholinesterase, in determining survival in patients supported with ECMO following cardiac surgery.
format Online
Article
Text
id pubmed-4059487
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40594872015-02-20 Choosing wisely - when to mend a broken heart with ECMO? Stephens, R Scott Fan, Eddy Crit Care Commentary Refractory cardiac shock in the cardiac surgical intensive care unit confers significant morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) has become a common intervention for refractory cardiogenic shock when other therapies have failed. However, it is difficult to predict who will benefit from this costly, resource-intensive, but potentially life-saving technology. Here, we discuss the utility of a novel biomarker, serum butylcholinesterase, in determining survival in patients supported with ECMO following cardiac surgery. BioMed Central 2014 2014-02-20 /pmc/articles/PMC4059487/ /pubmed/24602370 http://dx.doi.org/10.1186/cc13736 Text en Copyright © 2014 Stephens and Fan; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Stephens, R Scott
Fan, Eddy
Choosing wisely - when to mend a broken heart with ECMO?
title Choosing wisely - when to mend a broken heart with ECMO?
title_full Choosing wisely - when to mend a broken heart with ECMO?
title_fullStr Choosing wisely - when to mend a broken heart with ECMO?
title_full_unstemmed Choosing wisely - when to mend a broken heart with ECMO?
title_short Choosing wisely - when to mend a broken heart with ECMO?
title_sort choosing wisely - when to mend a broken heart with ecmo?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059487/
https://www.ncbi.nlm.nih.gov/pubmed/24602370
http://dx.doi.org/10.1186/cc13736
work_keys_str_mv AT stephensrscott choosingwiselywhentomendabrokenheartwithecmo
AT faneddy choosingwiselywhentomendabrokenheartwithecmo